A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

Phase 1 Terminated 3 enrolled Merck Sharp & Dohme LLC

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate MK0457 in combination with Dasatinib in patients with Chronic Myelogenous Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Efficacy and Safety will be evaluated.

Timeline

Start: 2007-10
Primary completion: 2007-11
Completion: 2007-11

Publications

Results Okabe S, Tauchi T, Ohyashiki K. Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells. Ann Hematol. 2010 Nov;89(11):1081-7. doi: 10.1007/s00277-010-0998-x. Epub 2010 Jun 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TOZASERTIB	Small molecule	20 mg/m2	Intravenous
Subject	TOZASERTIB	Small molecule	33 mg/m2	Intravenous
Subject	TOZASERTIB	Small molecule	64 mg/m2	Intravenous
Subject	TOZASERTIB	Small molecule	216 mg/m2	Intravenous
Background	dasatinib anhydrous	Small molecule	70 mg	Oral

A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

Summary

Timeline

Publications

Drugs

Indications